Bergen Brunswig Gets Out Of the Specialty Retail Business
Executive Summary
Bergen Brunswig Corp's recent announcement that it would sell the specialty pharmacy assets of its Stadtlander Drug Co. subsidiary hardly comes as a surprise. Stadtlander has performed poorly since it was acquired from Counsel Corp. eighteen months ago. Stadtlander is not alone: two other Bergen subsidiaries, PharMerica (which distributes drugs to long-term care facilities) and Bergen Brunswig Medical Corp., a supply business (which is also being sold), have also disappointed.If Bergen's expectations for Stadtlander were not met, say company officials, it was because Counsel's management misled them with respect to the specialty pharmacy's value. Indeed, Bergen sued Counsel, alleging that it was fraudulently induced into paying the price that it did for Stadtlander. That case is pending.So far, investors and analysts have reacted favorably to the Stadtlander sale. In addition to reducing Bergen's debt and eliminating a drag on earnings, parting with Stadtlander is seen as a way for Bergen to refocus its attentions on its core drug distribution business.
You may also be interested in...
Opportunism Knocks
In this era of pharmaceutical industry consolidation, large pharmaceutical companies, and in particular the newly-merged, taking stock of their increasing bulk, have been heard to say that they will drop products in development that don't have the potential to achieve at least $500 million in revenues. Big pharmas are also looking more critically at their small products already on the market. For these large companies, small products could prove to be a distraction that diverts resources away from potential blockbusters, the kinds of products that the companies will need to grow by 15% a year going forward. In theory, then, as pharmaceutical companies up-average product portfolios in favor of high-revenue producers and prune away redundant or non-strategic products in the aftermath of mergers, many more commercializable products should become available for licensing than ever before. That is the hope, anyway, of a handful of new specialty pharmaceutical companies formed to acquire on-the-market products with the aim of growing their sales through a variety of strategies. These companies avoid product development risk but bear risk of a different sort. To be successful, they must be able to continually acquire products that can grow, and not pay too much for them.
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.
UK MHRA Updates Assistive Tech And Borderline Regulations
Device classification themes were uppermost in April for the UK regulator, which issued key guidance in two areas prone to complexities. It also contributed to the MedTech Directorate’s one-year progress report.